Nevertheless, our findings showed that belimumab treatment led to changes in the composition of memory B cells associated with the resolution of exacerbation, which may contribute to the improvement of SLE through a mechanism in which BTLA engagement attenuates BCR- and BAFF-induced B cell intracellular signaling. This evidence concerns the gene BCR and systemic lupus erythematosus.